Darzalex 400mg Injection

Darzalex 400mg injection is a targeted therapy containing the active ingredient Daratumumab, a monoclonal antibody. Monoclonal antibodies are proteins that recognise and attach to specific targets on cancer cells, leading to their destruction. It is indicated for the treatment of multiple myeloma in adults aged 18 years or older.

Inform your doctor if you have a history of hepatitis B infection, as this medicine may cause reactivation of hepatitis B virus. This medicine may decrease platelet counts (which assist in blood clotting) and white blood cell counts (which help fight infections). Do not use Darzalex 400mg injection if you are allergic to Daratumumab or any other component of the medicine. This medicine is not recommended for children and adolescents.

Report any infusion-related reactions to your doctor, including swelling of the face, lips, mouth, tongue, or throat. Should infusion reactions occur, additional medication may be required, or the infusion rate may be reduced or discontinued. Notify your doctor if you follow a salt-restricted diet, as this medicine contains sodium.

Inform your doctor if you have a history of breathing problems such as asthma or chronic obstructive pulmonary disease, or if you have had shingles before starting treatment with Darzalex 400mg. This medicine may interfere with blood type testing results. You must inform your healthcare provider that you are being treated with this medicine prior to receiving any blood transfusions.

If you are pregnant or planning to become pregnant, inform your doctor. Effective contraception should be used during treatment and for three months after treatment.

Uses of Darzalex 400mg Injection: Treatment of multiple myeloma, a type of blood cancer Used alone or in combination with other cancer therapies Helps slow the progression of multiple myeloma Enhances the immune system's ability to attack cancer cells Reduces tumor burden and improves survival rates Used in newly diagnosed as well as relapsed/refractory multiple myeloma cases May be combined with corticosteroids, chemotherapy, or immunomodulatory drugs for better efficacy

Darzalex 400mg binds specifically to a protein called CD38 found on the surface of multiple myeloma cells. This binding can trigger the immune system to attack and kill the cancer cells.

A trained doctor or nurse should only administer Darzalex 400mg. Do not self-administer the injection. Your doctor will decide the dose and duration of your treatment based on the disease severity and other factors. It will be given as an intravenous infusion, and you will be monitored carefully for unwanted side effects.

Side effects are unwanted symptoms caused by medicines. Even though all medicines cause side effects, not everyone gets them. Serious Infusion reactions (itching, wheezing, chills, fever, throat tightness, runny nose, headache, low pressure) Changes in blood tests Decrease in blood cell counts Common Nausea, vomiting Back pain, muscle spasms Diarrhea Tiredness Shortness of breath Upper respiratory tract infection Tingling, numbness, or pain Constipation Trouble sleeping Dizziness Joint pain

If you experience any symptoms mentioned above, consult your doctor immediately. While undergoing treatment, use effective contraception and continue it for three months after stopping treatment. Darzalex 400mg is not recommended for children and adolescents under 18 years. Do not freeze the medicine. Before starting the treatment, inform your doctor about every underlying medical condition. Talk to your physician if you are on a salt-controlled diet, as this medicine contains sodium.